SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 124 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,830 | -41.3% | 126 | -15.4% | 0.00% | – |
Q2 2023 | $3,119 | -28.3% | 149 | -27.7% | 0.00% | – |
Q1 2023 | $4,351 | +144.2% | 206 | +194.3% | 0.00% | – |
Q4 2022 | $1,782 | -10.9% | 70 | 0.0% | 0.00% | – |
Q3 2022 | $2,000 | +100.0% | 70 | 0.0% | 0.00% | – |
Q2 2022 | $1,000 | 0.0% | 70 | +34.6% | 0.00% | – |
Q1 2022 | $1,000 | 0.0% | 52 | +23.8% | 0.00% | – |
Q3 2021 | $1,000 | – | 42 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |